# EvidenceDigest: When to Start Antihypertensive Therapy in Stage 1 Hypertension
Clinical bottom line
The decision to initiate antihypertensive therapy in patients with stage 1 hypertension should be individualized, taking into account cardiovascular risk factors, comorbid conditions, and patient preferences. Recent guidelines suggest that lifestyle modifications should be the first line of intervention, with pharmacotherapy considered for those with elevated cardiovascular risk or existing cardiovascular disease.
What the evidence shows
Current guidelines, such as those from the American College of Cardiology/American Heart Association (ACC/AHA), recommend starting antihypertensive medication in patients with stage 1 hypertension (systolic blood pressure 130-139 mmHg or diastolic blood pressure 80-89 mmHg) if they have a history of cardiovascular disease or a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 10% or higher (Whelton PK, et al. J Am Coll Cardiol 2018;71:e127-e248. PMID: 29146535).
A systematic review and meta-analysis of randomized controlled trials (RCTs) indicates that antihypertensive treatment in stage 1 hypertension can reduce the risk of cardiovascular events, particularly in individuals with high cardiovascular risk (Ettehad D, et al. Lancet 2016;387:957-967. PMID: 26724178). However, the absolute benefit is smaller in low-risk populations, suggesting that the decision to initiate therapy should be carefully weighed against potential side effects and patient preferences.
The SPRINT trial, a landmark study, demonstrated that intensive blood pressure control (targeting <120 mmHg systolic) significantly reduced cardiovascular events and mortality in high-risk patients, including those with stage 1 hypertension (SPRINT Research Group. N Engl J Med 2015;373:2103-2116. PMID: 26551272). Although this trial did not specifically focus on stage 1 hypertension, its findings support more aggressive management in high-risk individuals.
Caveats and uncertainty
While evidence supports the benefits of antihypertensive therapy in high-risk stage 1 hypertension patients, there is less clarity for those at lower risk. The potential for overtreatment and associated adverse effects, such as hypotension and electrolyte imbalances, must be considered. Additionally, the generalizability of trial results to diverse populations remains a concern, as many studies have predominantly included older adults and those with existing cardiovascular conditions.
The variability in risk assessment tools, such as the ASCVD risk calculator, can also lead to differences in treatment recommendations. Clinicians should be aware of these limitations and consider using multiple risk assessment strategies to guide decision-making.
How this may change practice
The evolving evidence base suggests a shift towards more personalized management of stage 1 hypertension, emphasizing the importance of comprehensive cardiovascular risk assessment. Clinicians may increasingly rely on risk calculators to guide treatment decisions, balancing the benefits of early pharmacotherapy against the risks of medication side effects.
In practice, this approach may lead to more targeted use of antihypertensive medications, reserving pharmacotherapy for those most likely to benefit while continuing to emphasize lifestyle modifications for all patients. Ongoing research and updates to clinical guidelines will be crucial in refining these strategies and ensuring optimal patient outcomes.